Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Systemic Lupus Erythematosus Pipeline Analysis

P&S Market Research-Systemic Lupus Erythematosus Pipeline Analysis report

Systemic Lupus Erythematosus Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: May 2017
Report Code: LS10944
Available Format: pdf
Pages: 172

Pipeline Overview

Systemic lupus erythematosus is a chronic inflammatory disease that involves swelling and pain, most commonly on face. The disease affects many parts of the body including skin, joints, kidneys, pleura, pericardium and brain. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. As of now there is no cure for systemic lupus erythematosus, but medical interventions and lifestyle changes can help in improving quality of life. The systemic lupus erythematosus can be mild to severe in its form. The cause of systemic lupus erythematosus is unknown, but it is most likely linked to genetic, environmental and hormonal factors. The chance of developing systemic lupus erythematosus is 10 times greater in women as compared to men.

Systemic lupus erythematosus includes symptoms such as oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is diagnosed by examining the symptoms, physical examination, X-rays and lab tests.

Systemic lupus erythematosus treatment involves a combination approach as number of organs are involved. The treatment consists immunosuppressive drugs that inhibit activity of the immune system. The most common approach to treat systemic lupus erythematosus is the use of hydroxychloroquine and corticosteroids including prednisone.

Pipeline Analysis

As of April 2017, the systemic lupus erythematosus pipeline comprises of approximately 57 active drug candidates in different stages of development.

 

NUMBER OF SYSTEMIC LUPUS ERYTHEMATOSUS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

Systemic Lupus Erythematosus Pipeline Analysis

 

Competitive Landscape

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

2500
Group License

Group License authorizes access of the publication upto 5 users.

3250
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

7000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment